CT1812 for Lewy Body Dementia
(COG1201 Trial)

Recruiting in Palo Alto (17 mi)

+37 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Cognition Therapeutics

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.

Research Team

Anthony Caggiano, MD

Principal Investigator

Cognition Therapeutics Inc.

Eligibility Criteria

This trial is for men and women aged 50-85 with mild to moderate Dementia with Lewy Bodies (DLB). Participants must have a certain score on a cognitive test and an MRI or CT scan that supports the DLB diagnosis without major brain abnormalities. People with other serious neurological diseases, psychiatric diagnoses like schizophrenia or bipolar disorder, unstable illnesses, or recent significant brain events cannot join.

Inclusion Criteria

MMSE 18-27 inclusive

My recent brain scans are consistent with DLB diagnosis and show no major issues.

I am between 50-85 years old and likely have Dementia with Lewy Bodies.

Exclusion Criteria

Clinical, laboratory findings or medical history consistent with:

I have a diagnosis of a specific type of dementia, not Alzheimer's.

I have a condition like ALS affecting my nervous system.

See 6 more

Treatment Details

Interventions

CT1812 (Small Molecule)

Trial OverviewThe study tests the safety and effectiveness of CT1812 in treating DLB. It's a multi-center trial where participants are randomly assigned to receive either CT1812 or a placebo over six months, without knowing which one they're getting.

Participant Groups

3Treatment groups

Active Control

Placebo Group

Group I: CT1812 300 mgActive Control1 Intervention

CT1812 300 mg

Group II: CT1812 100 mgActive Control1 Intervention

CT1812 100 mg

Group III: PlaceboPlacebo Group1 Intervention

Placebo